ReviewFrontiers in cell and developmental biology2025
MicroRNAs regulating apoptosis and delivery strategies for treating intervertebral disc degeneration.
Review in Frontiers in cell and developmental biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Identification and Experimental Validation of PANoptosis Key Genes for Constructing a PANoptosis Risk Diagnostic Model in Intervertebral Disc Degeneration.The journal of gene medicine · 2026Article
- Versatile Microgel Platform for Intervertebral Disc Degeneration Therapy: Targeting Pericyte-Mediated Fibrosis and Protecting Nucleus Pulposus Cells.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Ubiquitination in intervertebral disc degeneration: from mechanisms to potential therapeutic strategies.Journal of orthopaedic translation · 2026Review
- Context-dependent miRNA regulation in intervertebral disc degeneration: an IDD-focused dynamic network framework for stage-specific therapeutics.Frontiers in cell and developmental biology · 2026Article
- Apoptosis as an evolutionary battleground: pathogen pressure and the shaping of programmed cell death pathways.Frontiers in cell and developmental biology · 2026Review
- Integrating cells, scaffolds, and molecular regulation: a mechanobiological and translational review of bioengineering therapies for intervertebral disc degeneration.Frontiers in bioengineering and biotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Intervertebral disc degeneration (IDD) is a leading contributor to chronic low back pain (LBP), significantly impairing quality of life and imposing socioeconomic burdens globally. Current treatments fail to address the underlying pathology or restore intervertebral disc (IVD) function. IDD is multifactorial but strongly linked to nucleus pulposus cell (NPC) apoptosis. Gene therapy, particularly the use of microRNAs (miRNAs), holds promise for reversing IDD by targeting apoptotic pathways and enhancing the biological functions of NPCs. Given the avascular nature of IVD, effective delivery strategies are critical. Targeting strategies, such as NPC-targeting, which relies on cellular uptake through direct uptake, specific ligand‒receptor interactions and aptamer utilization, can significantly increase delivery efficacy. Additionally, organelle-targeting strategies that focus on mitochondria and the endoplasmic reticulum (ER) optimize therapeutic delivery. Coupled with these targeting methods, responsive delivery strategies that react to endogenous stimuli (such as pH, reactive oxygen species, and enzymes) and exogenous stimuli (including temperature, ultrasound, magnetism, and light) enable spatiotemporal release of therapeutic agents. This review summarizes the role of anti-apoptotic miRNAs in regulating NPC apoptosis and the latest advances in targeting and responsive delivery strategies to overcome the challenges associated with targeted therapeutic miRNA application, offering new insights into the treatment of IDD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.